Kerstin Kampa-Schittenhelm
Medizinische Onkologie und Hämatologie · Dept. I
Evaluation of apoptosis stimulating protein of TP53-1 (ASPP1/PPP1R13B) to predict therapy resistance and overall survival in acute myeloid leukemia (AML).
Schittenhelm M, Kaiser M, Győrffy B, Kampa-Schittenhelm K. Evaluation of apoptosis stimulating protein of TP53-1 (ASPP1/PPP1R13B) to predict therapy resistance and overall survival in acute myeloid leukemia (AML). Cell Death Dis 2024; 15:25.
10.01.2024Evaluation of apoptosis stimulating protein of TP53-1 (ASPP1/PPP1R13B) to predict therapy resistance and overall survival in acute myeloid leukemia (AML).
10.01.2024Cell Death Dis 2024; 15:25
Schittenhelm Marcus, Kaiser Max, Győrffy Balázs, Kampa-Schittenhelm Kerstin
Mutant driving the Warburg Effect in Mantle Cell lymphoma.
Kliebhan J, Besse A, Kampa-Schittenhelm K, Schittenhelm M, Driessen C. Mutant driving the Warburg Effect in Mantle Cell lymphoma. Clin Case Rep 2022; 10:e6296.
03.10.2022Mutant driving the Warburg Effect in Mantle Cell lymphoma.
03.10.2022Clin Case Rep 2022; 10:e6296
Kliebhan Johannes, Besse Andrej, Kampa-Schittenhelm Kerstin, Schittenhelm Marcus, Driessen Christoph
Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS).
Tsintari V, Walter B, Fend F, Overkamp M, Rothermundt C, Lopez C, Schittenhelm M, Kampa-Schittenhelm K. Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS). BMC cancer 2022; 22:725.
02.07.2022Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS).
02.07.2022BMC cancer 2022; 22:725
Tsintari Vasileia, Walter Bianca, Fend Falko, Overkamp Mathis, Rothermundt Christian, Lopez Charles D, Schittenhelm Marcus, Kampa-Schittenhelm Kerstin
ASPP2κ Is Expressed In Human Colorectal Carcinoma And Promotes Chemotherapy Resistance And Tumorigenesis
Rieger I, Tsintari V, Overkamp M, Fend F, Lopez C, Schittenhelm M, Kampa-Schittenhelm K. ASPP2κ Is Expressed In Human Colorectal Carcinoma And Promotes Chemotherapy Resistance And Tumorigenesis. Front Mol Biosci 2021; 8:727203.
05.11.2021ASPP2κ Is Expressed In Human Colorectal Carcinoma And Promotes Chemotherapy Resistance And Tumorigenesis
05.11.2021Front Mol Biosci 2021; 8:727203
Rieger Ingmar, Tsintari Vasileia, Overkamp Mathis, Fend Falko, Lopez Charles D, Schittenhelm Marcus, Kampa-Schittenhelm Kerstin
Epigenetic activation of O-linked β-N-acetylglucosamine transferase overrides the differentiation blockage in acute leukemia
Kampa-Schittenhelm K, Vogel W, Schleicher E, Bonzheim I, Mau-Holzmann U, Illing B, Akmut F, Ganief T, Dreher S, Blumenstock G, Haeusser L, Bühring H, Tsintari V, Bonin M, Haverkamp T, Schittenhelm M. Epigenetic activation of O-linked β-N-acetylglucosamine transferase overrides the differentiation blockage in acute leukemia. EBioMedicine 2020; 54:102678.
06.04.2020Epigenetic activation of O-linked β-N-acetylglucosamine transferase overrides the differentiation blockage in acute leukemia
06.04.2020EBioMedicine 2020; 54:102678
Kampa-Schittenhelm Kerstin, Vogel W, Schleicher E, Bonzheim I, Mau-Holzmann U A, Illing B, Akmut F, Ganief T, Dreher S T, Blumenstock G, Haeusser L, Bühring H J, Tsintari V, Bonin M, Haverkamp T, Schittenhelm Marcus
Alternative splicing of the tumor suppressor ASPP2 results in a stress-inducible, oncogenic isoform prevalent in acute leukemia
Schittenhelm M, Lopez C, Fend F, Mau-Holzmann U, Illing B, Akmut F, Bajrami Saipi M, Federmann B, Tsintari V, Walter B, Kampa-Schittenhelm K. Alternative splicing of the tumor suppressor ASPP2 results in a stress-inducible, oncogenic isoform prevalent in acute leukemia. EBioMedicine 2019; 42:340-351.
02.04.2019Alternative splicing of the tumor suppressor ASPP2 results in a stress-inducible, oncogenic isoform prevalent in acute leukemia
02.04.2019EBioMedicine 2019; 42:340-351
Schittenhelm Marcus, Lopez Charles Darin, Fend Falko, Mau-Holzmann Ulrike, Illing Barbara, Akmut Figen, Bajrami Saipi Mihada, Federmann Birgit, Tsintari Vasileia, Walter Bianca, Kampa-Schittenhelm Kerstin
Dasatinib overrides the differentiation blockage in a patient with mutant- D816V positive CBFβ-MYH11 leukemia
Kampa-Schittenhelm K, Vogel W, Bonzheim I, Fend F, Horger M, Kanz L, Soekler M, Schittenhelm M. Dasatinib overrides the differentiation blockage in a patient with mutant- D816V positive CBFβ-MYH11 leukemia. Oncotarget 2018; 9:11876-11882.
31.01.2018Dasatinib overrides the differentiation blockage in a patient with mutant- D816V positive CBFβ-MYH11 leukemia
31.01.2018Oncotarget 2018; 9:11876-11882
Kampa-Schittenhelm Kerstin, Vogel Wichard, Bonzheim Irina, Fend Falko, Horger Marius, Kanz Lothar, Soekler Martin, Schittenhelm Marcus
Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia
Kampa-Schittenhelm K, Frey J, Haeusser L, Illing B, Pavlovsky A, Blumenstock G, Schittenhelm M. Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia. Oncotarget 2017; 8:82897-82909.
07.08.2017Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia
07.08.2017Oncotarget 2017; 8:82897-82909
Kampa-Schittenhelm Kerstin, Frey Julia, Haeusser Lara A, Illing Barbara, Pavlovsky Ashly A, Blumenstock Gunnar, Schittenhelm Marcus
Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns
Kampa-Schittenhelm K, Salitzky O, Akmut F, Illing B, Kanz L, Salih H, Schittenhelm M. Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns. BMC cancer 2016; 16:25.
16.01.2016Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns
16.01.2016BMC cancer 2016; 16:25
Kampa-Schittenhelm Kerstin, Salitzky Olaf, Akmut Figen, Illing Barbara, Kanz Lothar, Salih Helmut Rainer, Schittenhelm Marcus
Attenuated expression of apoptosis stimulating protein of p53-2 (ASPP2) in human acute leukemia is associated with therapy failure
Schittenhelm M, Illing B, Ahmut F, Rasp K, Blumenstock G, Döhner K, Lopez C, Kampa-Schittenhelm K. Attenuated expression of apoptosis stimulating protein of p53-2 (ASPP2) in human acute leukemia is associated with therapy failure. PloS one 2013; 8:e80193.
27.11.2013Attenuated expression of apoptosis stimulating protein of p53-2 (ASPP2) in human acute leukemia is associated with therapy failure
27.11.2013PloS one 2013; 8:e80193
Schittenhelm Marcus, Illing Barbara, Ahmut Figen, Rasp Katharina Henriette, Blumenstock Gunnar, Döhner Konstanze, Lopez Charles D, Kampa-Schittenhelm Kerstin
Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia
Kampa-Schittenhelm K, Heinrich M, Akmut F, Rasp K, Illing B, Döhner H, Döhner K, Schittenhelm M. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. Mol Cancer 2013; 12:46.
24.05.2013Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia
24.05.2013Mol Cancer 2013; 12:46
Kampa-Schittenhelm Kerstin, Heinrich Michael Charles, Akmut Figen, Rasp Katharina Henriette, Illing Barbara, Döhner Hartmut, Döhner Konstanze, Schittenhelm Marcus
Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms
Kampa-Schittenhelm K, Heinrich M, Akmut F, Döhner H, Döhner K, Schittenhelm M. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. Mol Cancer 2013; 12:19.
07.03.2013Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms
07.03.2013Mol Cancer 2013; 12:19
Kampa-Schittenhelm Kerstin, Heinrich Michael Charles, Akmut Figen, Döhner Hartmut, Döhner Konstanze, Schittenhelm Marcus
The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin
Schittenhelm M, Kampa-Schittenhelm K, Yee K, Heinrich M. The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin. Cell Cycle 2009; 8:2621-30.
24.08.2009The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin
24.08.2009Cell Cycle 2009; 8:2621-30
Schittenhelm Marcus, Kampa-Schittenhelm Kerstin, Yee Kevin W H, Heinrich Michael C